Awakn Life Sciences Corp.: Awakn Life Sciences Reports Strong Q3 2022 Results with 27% Revenue Growth

And continued successful execution of R&D and Commercialization strategies
Toronto, Ontario--(Newsfile Corp. - December 15, 2022) - Awakn Life Sciences Corp.(NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn")

Related Keywords

United Kingdom ,New York ,United States ,Norway ,Bristol ,City Of ,Toronto ,Ontario ,Canada ,London ,America ,Canadian ,Gordo Whittaker ,Catalent Zydis ,Anthony Tennyson ,Linkedin Facebook ,Awakn Life Sciences ,Drug Development Company To Deepen Ip Moat ,International Financial Reporting Standards ,Awakn Life Sciences Signs Drug Development Agreement ,Awakn Life Sciences Corp ,Awakn Life Sciences Signs Agreement ,Newsfile Corp ,Awakn Life Sciences Announces Signing Of Lease ,First Licensing Partnership Agreement ,Awakn Life Sciences Expands Commercial Operations ,Awakn Life Sciences Signs ,Third Licensing Partnership Agreement ,Life Sciences Corp ,Alcohol Use Disorder ,Chief Executive Officer ,Project Kestrel ,Life Sciences Expands Commercial Operations ,Licensing Partnership Agreement ,Expands Commercial Operations ,Life Sciences Signs Drug Development Agreement ,Conduct Feasibility Studies ,Improve Differentiation ,Life Sciences Signs Agreement ,Leading Drug Development Company ,Life Sciences Signs ,North America ,Life Sciences Announces Location ,Larger Oslo ,Life Sciences Announces Signing ,Second Clinic ,Financial Highlights ,Oslo Awakn ,Life Sciences ,Awakn Life ,Awakn ,Life ,Ciences ,Orp ,Reports ,Strong ,022 ,Results ,Revenue ,Growth ,